High Dose Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation as a First Line Treatment for Multiple Myeloma: A Korean Multicenter Study

Journal of Korean Medical Science

Volumn 18, Issue 5, 2003, Pages 673-678

  Bang, Soo Mee ^a   Cho, Eun Kyung ^a   Suh, Cheolwon ^b   Yoon, Sung Soo ^c   Seong, Chu Myung ^d   Cho, Kyung Sam ^e   Kang, Yoon Goo ^f   Park, Seonyang ^g   Ahn, Myung Ju ^h   Park, Young Suk ⁱ   Oh, Doyeun ^j   Kim, Hugh C ^k   Jung, Chul Won ^l   Kim, Samyong ^m   Lee, Jae Hoon ^a  

^a Gachon University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Ewha Womans University School of Medicine   (South Korea)

^e Kyung Hee University Hospital   (South Korea)

^f Cancer Center Hospital   (South Korea)

^g Seoul National University College of Medicine   (South Korea)

^h Hanyang University College of Medicine   (South Korea)

ⁱ Hallym University College of Medicine   (South Korea)

^j CHA University   (South Korea)

^k Ajou University School of Medicine   (South Korea)

^l Chung Ang University College of Medicine   (South Korea)

^m Chungnam National University College of Medicine   (South Korea)

more..

Author keywords

Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation Autologous

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; MELPHALAN; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG MEGADOSE; FEMALE; HEART FUNCTION; HUMAN; INFECTION; KIDNEY FUNCTION; KOREA; LIVER TOXICITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE MYELOMA; MYCOSIS; NAUSEA; NEPHROTOXICITY; PATIENT SELECTION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; STEM CELL MOBILIZATION; VIRUS INFECTION;

EID: 9144250230     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2003.18.5.673     Document Type: Article

References (25)

1. Central Cancer Registry Center and Ministry of Health and Welfare. Annual Report of the Central Cancer Registry in Korea. 1999.
2. Yang SH, Kim TY, Kim BK, Ko YW, Kwak DK, Kim NK, Kim S. A statistical study of multiple myeloma in Korea. Korean J Hematol 1995; 30: 345-61.
3. Rivers SL, Patno ME. Cyclophosphamide vs melphalan in treatment of plasma cell myeloma. JAMA 1969; 207: 1328-34.
4. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832-42.
5. Belch A, Shelley W, Bersagel D, Wilson K, Klimo P, White D, Willan A. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988; 57: 94-9.
6. Kyle RA. Long term survival in multiple myeloma. N Engl J Med 1983; 308: 314-6.
7. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822-4.
8. Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S, Horwitz L. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869-72.
9. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996; 335: 91-7.
10. Fermand JP, Ravaud P, Katsahian S, Divine M, Leblond V, Belanger C, Dreyfus F, Marco M, Chevret S, Brechignac S, Brouet JC. High dose therapy and autologous blood stem cell transplantation versus conventional treatment in multiple myeloma: results of a randomized trial in 190 patients 55 to 65 years of age. Blood 1999; 94 (Suppl 1): 396a (abstr.).
11. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-23.
12. Samson D, Gaminara E, Newland A, Van de Pette J, Kearney J, McCarthy D, Joyner M, Aston L, Mitchell T, Hamon M, Barett AJ, Evans M. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989; 2: 882-5.
13. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
14. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, Macro M, Pertuiset E, Dreyfus F, Mariette X, Boccacio C, Brouet JC. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-6.
15. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Français du Myélome 9502 randomized trial. Blood 2002; 99: 731-5.
16. Moreau P, Harousseau JL, Wijdenes J, Morineau N, Milpied N, Bataille R. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rate in advanced multiple myeloma. Br J Haematol 2000; 109: 661-4.
17. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hullen C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R. Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the "Intergroupe Français du Myélome" (IFM 94). Blood 2002; 99 (Suppl 1): 7a (abstr.).
18. Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Crookewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, Van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, Van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MM, Buijt I, Lokhorst HM, Dutch-Belgian Hemato-Oncology Cooperative study Group. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple meyloma: A prospective randomized phase III study. Blood 2003; 101: 2144-51.
19. Cavo M, Tosi P, Zamagni E, Cellini C, Ronconi S, Vivo AD, Cangini D, Baccarani M, Sante T, Caro M, Tosi P, Zamagni E. The "Bologna 96" clinical trial of single vs. double autotransplants for previously untreated multiple myeloma patients. Blood 2002; 99 (Suppl 1): 179a (abstr.).
20. Fermand JP, Marolleau JP, Alberti C, Divine M, Leblond V, Macro M, Jaccard A, Belanger C, Maloisel F, Dreyfus F, Royer B, McIntyre E, Brouet JC, for the group "Myélome-Autogreffe". In single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34 enriched ABSC: preliminary results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM). Blood 2001 ; 98 (Suppl 1): 815a (abstr.).
21. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, White M, DiPersio J, Anderson KC, Berenson J. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771-9.
22. Goldschmidt H, Bouko Y, Bourhis JH, Greinix H, Salles G, Derigs G, Feremans W, Hegenbart U, Bakkus M, Samson D, Gahrton G, Pico JL, Apperly J. CD 34+ selected PBPCT results in an increased infective risk without prolongation of event free survival in newly diagnosed myeloma: a randomized study from the EBMT. Blood 2000; 96: 558a (abstr).
23. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, Montes A, Hickish T, Nicolson M, Johnson P, Treleaven J, Raymond J, Gore M. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998; 102: 495-502.
24. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi NC, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P, Crowley J. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-10.
25. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, Lai JL, Leleu X, Jouet JP, Bauters F, Harousseau JL, Bataille R, Mary JY. Intergroupe Français du Myélome. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-71.